Effect of different steroids in ALL cancer patients
Not Applicable
Completed
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
Newly diagnosed patients of acute lymphoblastic leukemia (both B-ALL & T-ALL), between 1 year to 24 years of age, of any gender, where informed consent of parent/guardian is available
Exclusion Criteria
1.Infantile acute lymphoblastic leukemia (age < 1 year).
2.Patients of lymphoblastic lymphoma (LBL).
3.Relapsed cases of acute lymphoblastic leukemia.
4.Patients who have received dexamethasone, prednisolone or any other chemotherapy within 4 weeks of enrollment in study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare bone marrow minimal residual disease (MRD) response by flowcytometry on day 33 of induction phase chemotherapy in the dexamethasone and prednisolone treatment groupsTimepoint: 0 days and 33 days
- Secondary Outcome Measures
Name Time Method To compare Day 33 bone marrow morphological response in the two treatment groups. <br/ ><br>2. To compare Day 15 bone marrow morphological response & MRD status in the two treatment groups as per protocol. <br/ ><br>3. To compare the toxicity profile in the two treatment groups â?? adverse events of any grade, and adverse events of grade 3-4 (CTCAE- Common Terminology Criteria For Adverse Events Version 5). <br/ ><br>Timepoint: 0 days and 33 days